Kunal Kamble, sr. technical research analyst at Bonanza, has recommended buying shares of Wockhardt, TFCI, and HBL Engineering today
The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.
In the March quarter (Q4FY26), Wockhardt posted net profit year-on-year (Y-o-Y) of ₹166 crore, as compared to a net loss of ₹25 crore a year ago
According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,
The company said the United States Food and Drug Administration (USFDA) has formally accepted the New Drug Application (NDA) for its first-in-class antibiotic 'Zaynich'